Cargando…

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice

PURPOSE: To report long-term efficacy and treatment outcomes of the combination therapy for treating macular oedema (MO) in retinal vein occlusions (RVOs) from a real-world UK practice. METHODS: The initial reported 66 RVO patients with MO treated with combination therapy (initial Ranibizumab, later...

Descripción completa

Detalles Bibliográficos
Autores principales: Horner, Faye, Lip, Peck Lin, Mushtaq, Bushra, Chavan, Randhir, Mohammed, Bashar, Mitra, Arijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108880/
https://www.ncbi.nlm.nih.gov/pubmed/32273680
http://dx.doi.org/10.2147/OPTH.S241044
_version_ 1783512855973199872
author Horner, Faye
Lip, Peck Lin
Mushtaq, Bushra
Chavan, Randhir
Mohammed, Bashar
Mitra, Arijit
author_facet Horner, Faye
Lip, Peck Lin
Mushtaq, Bushra
Chavan, Randhir
Mohammed, Bashar
Mitra, Arijit
author_sort Horner, Faye
collection PubMed
description PURPOSE: To report long-term efficacy and treatment outcomes of the combination therapy for treating macular oedema (MO) in retinal vein occlusions (RVOs) from a real-world UK practice. METHODS: The initial reported 66 RVO patients with MO treated with combination therapy (initial Ranibizumab, later optional addition of Ozurdex and laser) were followed up to Year 3: visual acuity (VA) and central retinal thickness (CRT) were analysed against baseline and previous Year 1 results. Safety and adverse events were also recorded. RESULTS: Baseline LogMAR VA of 0.71 (Snellen 6/30) improved to 0.48 (Snellen 6/18) at Year 3 (p=0.006); 63% experienced VA improvement (40% improved ≥3 lines), 27% had worse vision. Stability of mean VA (6/18) was already achieved at first post-loading phase review and was maintained in each subsequent year. Statistically significant CRT improvement was noted in each year (Year 3 median CRT=264µm) compared to baseline (median CRT=531µm). There was a reduction in the mean number of total injections to 2.5 in Year 3 (vs 5.5 in Year 1). Comparing Year 3 against Year 1, mean Ranibizumab injection frequency was 2.1 vs 4.3; mean Ozurdex injection frequency was 0.2 vs 1.1. In Year 3, 39.6% of patients did not require any form of injections, laser frequency was also reduced to 22.9% (vs 81.8% in Year 1). There was no endophthalmitis in the cohort, one progressed to neovascular glaucoma in Year 2 and mortality rate was recorded as 6%. CONCLUSION: Our real-world clinical practice for RVO patients using a combined therapy is associated with good long-term VA and anatomical outcomes with less intravitreal re-treatment rates.
format Online
Article
Text
id pubmed-7108880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71088802020-04-09 Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice Horner, Faye Lip, Peck Lin Mushtaq, Bushra Chavan, Randhir Mohammed, Bashar Mitra, Arijit Clin Ophthalmol Original Research PURPOSE: To report long-term efficacy and treatment outcomes of the combination therapy for treating macular oedema (MO) in retinal vein occlusions (RVOs) from a real-world UK practice. METHODS: The initial reported 66 RVO patients with MO treated with combination therapy (initial Ranibizumab, later optional addition of Ozurdex and laser) were followed up to Year 3: visual acuity (VA) and central retinal thickness (CRT) were analysed against baseline and previous Year 1 results. Safety and adverse events were also recorded. RESULTS: Baseline LogMAR VA of 0.71 (Snellen 6/30) improved to 0.48 (Snellen 6/18) at Year 3 (p=0.006); 63% experienced VA improvement (40% improved ≥3 lines), 27% had worse vision. Stability of mean VA (6/18) was already achieved at first post-loading phase review and was maintained in each subsequent year. Statistically significant CRT improvement was noted in each year (Year 3 median CRT=264µm) compared to baseline (median CRT=531µm). There was a reduction in the mean number of total injections to 2.5 in Year 3 (vs 5.5 in Year 1). Comparing Year 3 against Year 1, mean Ranibizumab injection frequency was 2.1 vs 4.3; mean Ozurdex injection frequency was 0.2 vs 1.1. In Year 3, 39.6% of patients did not require any form of injections, laser frequency was also reduced to 22.9% (vs 81.8% in Year 1). There was no endophthalmitis in the cohort, one progressed to neovascular glaucoma in Year 2 and mortality rate was recorded as 6%. CONCLUSION: Our real-world clinical practice for RVO patients using a combined therapy is associated with good long-term VA and anatomical outcomes with less intravitreal re-treatment rates. Dove 2020-03-27 /pmc/articles/PMC7108880/ /pubmed/32273680 http://dx.doi.org/10.2147/OPTH.S241044 Text en © 2020 Horner et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Horner, Faye
Lip, Peck Lin
Mushtaq, Bushra
Chavan, Randhir
Mohammed, Bashar
Mitra, Arijit
Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title_full Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title_fullStr Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title_full_unstemmed Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title_short Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
title_sort combination therapy for macular oedema in retinal vein occlusions: 3-year results from a real-world clinical practice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108880/
https://www.ncbi.nlm.nih.gov/pubmed/32273680
http://dx.doi.org/10.2147/OPTH.S241044
work_keys_str_mv AT hornerfaye combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice
AT lippecklin combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice
AT mushtaqbushra combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice
AT chavanrandhir combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice
AT mohammedbashar combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice
AT mitraarijit combinationtherapyformacularoedemainretinalveinocclusions3yearresultsfromarealworldclinicalpractice